Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2006

Cheng T-, Brzostek S, Ando O, Van Scoy S, K Kumar P, Reich NC. Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection. J Immunol. 2006;176(12):7462-70.

Roviezzo F, Bucci M, Delisle C, Brancaleone V, Di Lorenzo A, Mayo IP, et al. Essential requirement for sphingosine kinase activity in eNOS-dependent NO release and vasorelaxation. FASEB J. 2006;20(2):340-2.

2005

Roviezzo F, Bucci M, Brancaleone V, Di Lorenzo A, Geppetti P, Farneti S, et al. Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes. Arterioscler Thromb Vasc Biol. 2005;25(11):2349-54.

Da Wu K-, Cho YS, Katz J, Ponomarev V, Chen-Kiang S, Danishefsky SJ, et al. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci U S A. 2005;102(30):10640-5.

Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11(1):63-70.

Zabaronick SR, Tyler JK. The histone chaperone anti-silencing function 1 is a global regulator of transcription independent of passage through S phase. Mol Cell Biol. 2005;25(2):652-60.

Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med. 2005;353(22):2342-51.

Rand J, Eerden PV, Wu XX, Chazotte C. Defective annexin A5 crystallization: a mechanism for pregnancy losses in the antiphospholipid syndrome. Thromb Res. 2005;115 Suppl 1:77-81.

Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle. 2005;4(9):1131-3.

Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem. 2005;280(26):25134-45.